Copenhagen Firm Brings AI Eye Tests to Gulf Eyewear Giant
OptikosPrime partners with Eyewa to use smartphone cameras for clinical-grade vision checks, removing a major barrier in the eyewear purchase process.
Key points
- OptikosPrime partners with Eyewa to integrate AI vision diagnostics into the Gulf eyewear market.
- Trials with 14,000 patients showed an error margin of less than 0.51 diopters, matching clinical standards.
- The technology uses standard smartphone cameras to replace the need for initial optometrist visits.
Buying new glasses often requires a trip to a clinic and a session with heavy, stationary diagnostic equipment. A new partnership aims to replace that physical hassle with a simple smartphone photo. OptikosPrime, a Copenhagen-based technology firm, has integrated its artificial intelligence vision engine into the retail platform of Eyewa, a major eyewear retailer in the Middle East.
The collaboration targets a specific friction point in the consumer journey: the lack of an up-to-date prescription. By using a standard mobile camera, customers can now determine their refractive error without visiting an optometrist first. This approach shifts the initial diagnostic step from a specialized clinic to the user's pocket, potentially streamlining the entire purchasing process.
Removing the prescription barrier
Eyewa operates both online and in physical stores across the Gulf Cooperation Council. Despite this broad reach, company officials noted that uncertainty about one's prescription remains the single biggest hurdle for shoppers. François-Xavier Jombart, Chief Optical Officer at Eyewa, stated that integrating clinical-grade AI removes this roadblock. The system allows customers to perform a quick self-assessment, turning a traditional barrier into an effortless digital step.
This move addresses a common issue in e-commerce known as cart abandonment. Many customers drop out of the buying process because they do not know their exact numbers or are unwilling to schedule a separate appointment to find out. By embedding the diagnostic tool directly into the retail ecosystem, the companies hope to reduce friction and provide immediate confidence in the product selection.
Testing accuracy against clinical standards
Skepticism toward mobile health tools is common due to variable lighting and hand stability. OptikosPrime addressed these concerns through extensive real-world trials. Conducted alongside the humanitarian organization Sightsavers, the tests evaluated over 14,000 patients across Africa and South Asia. The goal was to verify if a smartphone could match the precision of high-end autorefractors used in professional clinics.
The results indicated a mean absolute error of less than 0.51 diopters. This level of accuracy is considered standard for clinical use. The algorithms account for spherical aberrations and device variability in real time. Independent validation from the Karolinska Institutet confirmed the robustness of the performance, providing a scientific basis for the technology's commercial rollout.
Independence as a strategic choice
OptikosPrime previously declined acquisition offers from large multinational industry players. The company chose to remain independent to safeguard its core mission. This decision was made to avoid what are often called killer acquisitions, where promising digital health technologies are bought and then shelved to protect existing legacy revenue streams.
Ståle Fredlund Husby, Co-founder and COO of OptikosPrime, stated that the partnership with Eyewa represents the future they have been building toward. The company believes phone-based vision assessment will become a natural part of the customer journey. This partnership marks the transition from field validation to major commercial deployment in the Gulf region.
